Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.

NCT01991340 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01991340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01991340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
November 30, 2008
Completion date
February 28, 2013
Enrollment
657 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer